Targeting Immunological Pathways in Moderate to Severe Ulcerative Colitis

1.50 CME
90 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Targeting Immunological Pathways in Moderate to Severe Ulcerative Colitis

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Genentech, Inc.


Activity Description

Faculty review the latest evidence about investigational agents with unique mechanisms of action in late-stage development for ulcerative colitis (UC) and evaluate new clinical data on the efficacy and safety of therapeutic agents that target the immunological pathways of UC.


Target Audience

The intended audience for this activity is gastroenterologists, advanced practice providers, and other health care professionals involved in the management of patients with ulcerative colitis.


Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Assess the latest evidence about investigational agents with unique mechanisms of action in late-stage development for the treatment of moderate to severe ulcerative colitis.
  • Evaluate new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe ulcerative colitis.
  • Compare therapeutic regimens for moderate to severe ulcerative colitis in terms of their ability to improve outcomes in patients who are tumor necrosis factor (TNF inhibitor)-naïve, as well as those who have received TNF inhibitors.

Activity Chair

Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL


Faculty

Christina Y. Ha, MD, FACG, AGAF
Associate Professor of Medicine
Inflammatory Bowel Disease Center
Cedars-Sinai
Los Angeles, CA

Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and
Mount Sinai Health System
New York, NY


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 12, 2020, through August 11, 2021.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the poll and pretest questions, view the activity, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Activity Chair and Faculty report the following relationship(s)

Christina Y. Ha, MD, FACG, AGAF
Consulting Fee: AbbVie, Genentech, IBD Remedy, Imedex, Janssen, Pfizer, Prova Education, Salix, Takeda
Speakers Bureau: AbbVie

Stephen B. Hanauer, MD
Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Takeda, TiGenix, UCB Pharma, VHsquared
Speakers Bureau: AbbVie, Janssen, Takeda
Contracted Research: (paid to institution): AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB Pharma
Data and Safety Monitoring Board: Arena Pharmaceuticals, Bristol-Myers Squibb

Bruce E. Sands, MD, MS
Consulting Fee: AbbVie, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion, Genentech, F. Hoffmann-La Roche AG, Immunic AG, Ironwood Pharmaceuticals, Janssen, Lilly, Morphic Therapeutic, Oppilan, OSE Immunotherapeutics, Otsuka, Pfizer, Prometheus, RedHill Biopharma, Shire, Takeda, Target PharmaSolutions, Theravance

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com